NCT03684655View on ClinicalTrials.gov

Imaging Immune Activation in HIV by PET-MR

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

October 1, 2025

Study Completion Date

November 1, 2025

Conditions
HIV Infections
Interventions
DRUG

[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)

\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.

Trial Locations (1)

94110

RECRUITING

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

University of California, San Francisco

OTHER

lead

CellSight Technologies, Inc.

INDUSTRY